Stryker's income up 20% on 6% sales increase:
This article was originally published in Clinica
Executive Summary
Stryker's first-quarter sales increased 6% to $254 million, while net income rose 20% to $36 million. Kalamazoo, Michigan-based Stryker's domestic sales were up 14% to $171 million and were boosted by strong shipments of endoscopic equipment, powered surgical instruments and orthopaedics implants. International sales, hit by lower business to the Asian market and the exchange rate effects, fell 8% to $82 million.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.